# Intra-arterial infusion of bevacizumab for the treatment of peritoneal metastatic high-grade renal cell carcinoma: a case report

**Authors:** Song Jin, Chaoming Dai, Xiaomeng Dai, Peng Zhao, Bin Zhou, Jizhou Zhang, Weijia Fang

PMC · DOI: 10.3389/fimmu.2026.1686650 · Frontiers in Immunology · 2026-03-09

## TL;DR

A patient with advanced kidney cancer showed improvement after receiving bevacizumab artery infusion for abdominal metastases.

## Contribution

Demonstrates successful use of bevacizumab embolization for peritoneal metastases in stage IV RCC.

## Key findings

- Abdominal artery infusion of bevacizumab led to partial remission in a patient with extensive peritoneal metastases.
- The treatment was well-tolerated and showed lesion shrinkage during follow-up.
- This approach offers a potential local treatment option for metastatic RCC.

## Abstract

Metastatic renal cell carcinoma (mRCC) is a common type of urologic malignancy with limited systemic treatment, especially for extensive metastatic lesions in the peritoneum and greater omentum.

A 35-year-old male patient was admitted to the hospital with left lumbar pain, leading to the discovery of left renal mass. He subsequently underwent a nephrectomy, with postoperative pathology confirming RCC. Following surgery, he received three cycles of interleukin-2 therapy. Within 5 months of nephrectomy, related examinations confirmed tumor recurrence and metastasis, and palliative surgery was performed. Postoperative pathology confirmed high-grade RCC, diagnosed as stage IV with pancreatic, adrenal, and splenic metastases. The patient then underwent first-line treatment with ICI (Immune Checkpoint Inhibitors) in combination with pezopanib for 9 months before progressing and then changing to second-line treatment with ICI in combination with axitinib for 2 months before progressing again. The patient was subsequently screened for clinical studies and rapidly progressed to extensive abdominal metastases after 1 month. The patient was then treated with bevacizumab abdominal artery perfusion embolization and achieved partial remission. Subsequent systemic therapy was changed to everolimus combined with voronib targeted therapy until now, and the lesion has continued to shrink on multiple follow-ups in between.

Abdominal arterial infusion of bevacizumab embolization provides a feasible local treatment option for peritoneal metastases in stage IV RCC, warranting further clinical exploration.

## Linked entities

- **Chemicals:** axitinib (PubChem CID 3086685), everolimus (PubChem CID 6442177)
- **Diseases:** renal cell carcinoma (MONDO:0005086)

## Full-text entities

- **Diseases:** tumor (MESH:D009369), Metastatic renal cell carcinoma (MESH:C538445), left renal mass (MESH:C536030), RCC (MESH:D002292), urologic malignancy (MESH:D014571), metastases (MESH:D009362), pancreatic, (MESH:D010195), lumbar pain (MESH:D010146)
- **Chemicals:** bevacizumab (MESH:D000068258), axitinib (MESH:D000077784), everolimus (MESH:D000068338), pezopanib (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13006611/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13006611/full.md

## References

13 references — full list in the complete paper: https://tomesphere.com/paper/PMC13006611/full.md

---
Source: https://tomesphere.com/paper/PMC13006611